louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01240096: Mirtazapine Versus Placebo in Functional Dyspepsia
Official title: Phase 4 Study of Mirtazapine in Functional Dyspepsia Patients With Weight Loss
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Functional Dyspepsia
Keywords: Functional dyspepsia
Weight loss
Mirtazapine
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2010-11-15
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Double-blind randomized controlled trials of 8 weeks mirtazapine 15 mg daily or placebo, followed by 8 weeks of open-label mirtazapine 15 mg daily

Detailed description: Double-blind randomized controlled trials of 8 weeks mirtazapine 15 mg or placebo, followed by 8 weeks of open-label mirtazapine

Two weeks run-in, 8 weeks randomized, 8 weeks open label

Assessments include

* dyspepsia questionnaire
* Nepean dyspepsia index
* Daily diary
* Vital signs

Eligibility criteria: Inclusion Criteria:

* Functional dyspepsia according to Rome II criteria
* Weight loss of \> 5% body weights

Exclusion Criteria:

* Organic GI pathology
* History of upper gi tract surgery
* Major depression or anxiety
* Use of antidepressants in the last 2 months
* Prokinetic drugs or spasmolytic drugs
* Analgesic use (except paracetamol)
* Pregnancy or lactation

Primary outcomes:
measure: Difference in dyspepsia symptom scores week 8 versus week 0
timeFrame: Week 8 compared to week 0
Secondary outcomes:
measure: Individual symptom severities
timeFrame: Week 8 compared to week 0
measure: Nepean dyspepsia index for quality of life in functional dyspepsia
timeFrame: Week 8 compared to week 0
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: University Hospitals
state: Vlaanderen
Study officials:
affiliation: Universitaire Ziekenhuizen KU Leuven
name: Jan Tack, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tack J, Ly HG, Carbone F, Vanheel H, Vanuytsel T, Holvoet L, Boeckxstaens G, Caenepeel P, Arts J, Van Oudenhove L. Efficacy of Mirtazapine in Patients With Functional Dyspepsia and Weight Loss. Clin Gastroenterol Hepatol. 2016 Mar;14(3):385-392.e4. doi: 10.1016/j.cgh.2015.09.043. Epub 2015 Oct 30.
Clinical trial NCT01227096: Randomized Controlled Trial of the Effects of Electroacupuncture Preconditioning in Children Undergoing Cardiac Surgery
Official title: National Natural Science Foundation of China
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Congenital Heart Defects
Keywords: electroacupuncture pediatric cardioprotection
Lead sponsor: Air Force Military Medical University, China
Sponsor class: OTHER
Collaborators: name: National Natural Science Foundation of China
First posted: 2010-10-25
Enrollment: 60
Sex: ALL
Minimum age (years): 2
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 2-12 years old children undergoing all types of open-heart surgery were included.

Brief summary: The purpose of this study is to determine whether electroacupuncture preconditioning would provide protection against myocardial Ischemic-Reperfusion injury and systemic inflammation in children undergoing CPB for repair of congenital heart defects.

Detailed description: 2-12 years old children undergoing repair of congenital heart defects were included, except for those with server pulmonary arterial hypertension, chromosomal defects, airway and parenchymal lung disease, immunodeficiency, or blood disorders were excluded. Children were equal randomized to EAPC(electroacupuncture preconditioning)or control group. Electroacupuncture was administered on the bilateral P6 acupoint after anesthesia induction, but prior to surgery in EAPC group. Control patients underwent sham placement of the electrode the arm without stimulation. The duration of cardiopulmonary bypass and aortic cross-clamp time was recorded. Myocardial injury was assessed by cardiac heart-type fatty acid-binding protein (HFAP) and cardiac troponin I (cTnI\>0.40 ng/mL). 8-isoprostane , C-reactive protein, cytokines were measured pre- and postoperatively.

Eligibility criteria: Inclusion Criteria:

* Aged 2-12 years children undergoing repair of congenital heart defects without server pulmonary arterial hypertension or systematic disease.
* Get an informed consent from parental.

Exclusion Criteria:

* Patient's age is less than 2 years or more than 12 years.
* Patient with isolated atrial septal defect undergoing repair via thoracoscope completion.
* Patients with chromosomal defects, airway and parenchymal lung disease, immunodeficiency, or blood disorders.
* Patients without an informed consent from parental.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Hospital
state: Shanxi
Study officials:
affiliation: Department of Anesthesiology of Xijing Hospital
name: Xin-Li Ni, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Xijing Hospital of Fouth Military Medical University
name: Li-Ze Xiong, PhD
role: STUDY_CHAIR
affiliation: Department of Anesthesiology of Xijing Hospital
name: Qiang Wang, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02767596: Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog
Official title: A Pilot Single-Arm Open-Label Study to Evaluate the Efficacy of Treatment With Lixisenatide in Diabetes Mellitus Type 2 Patients With Failure of Other GLP-1 Analog
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Diabetes Mellitus Type 2
Keywords: Type 2 Diabetes Mellitus
treatment
GLP-1
Lead sponsor: Laniado Hospital
Sponsor class: OTHER
First posted: 2016-05-10
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study aims to examine the effectiveness of the short acting GLP-1 analog, Lixisenatide to achieve glycemic control in type 2 diabetes patients, in patients with failure of long acting GLP-1 analog.

Patients who fail to achieve significant improvement in diabetes control on basal insulin and Liraglutide will be switched to basal insulin and lixisenatide treatment for 12 weeks. The primary outcomes will be changes in HBA1C and weight.


Eligibility criteria: Inclusion Criteria:

Type Diabetes Mellitus on combination of basal insulin therapy and GLP1 analog, with secondary failure of non-fasting glycemic control

Exclusion Criteria:

* Pregnant or lactating woman
* Renal failure (eGFR\<30)

Primary outcomes:
measure: Change in hemoglobin A1c
timeFrame: 16 weeks
measure: Change in body weight
timeFrame: 16 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Netanya
country: Israel
facility: Bildirici Diabetes Center, Laniado Hospital
Study officials:
References:
Clinical trial NCT05298696: Efficacy of Cilostazol in Prevention of Peripheral Neuropathy
Official title: Safety and Efficacy of Cilostazol in Prevention of Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Peripheral Neuropathy
Breast Cancer
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2022-03-28
Enrollment: 71
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: There are several mechanisms concerning pathophysiology of paclitaxel induced peripheral neuropathy. One of the main mechanisms is induction of Schwann cell dedifferentiation by paclitaxel. At the preclinical level, cilostazol potently inhibited paclitaxel-induced dedifferentiation of cultured Schwann cells, yet this positive effect have not been clinically investigated.


Eligibility criteria: Inclusion Criteria:

1. Breast cancer patients who will receive paclitaxel post-anthracycline therapy.
2. Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2.
3. Adequate bone marrow function (white blood count ≥4,000/mm3, platelet count≥100,000/mm3), liver function (serum total bilirubin \<1.5 mg/dl), renal function (creatinine \< 1.5 mg/dl).

Exclusion Criteria:

1. Patients with signs and symptoms of clinical neuropathy at baseline.
2. Patients with diabetes mellitus or alcoholic disease.
3. Patients receiving vitamin/ supplementation drugs that interfere with the study intervention.

Primary outcomes:
measure: Incidence of chemotherapy induced-peripheral neuropathy using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria
timeFrame: 8 weeks post intervention
Secondary outcomes:
measure: Severity of chemotherapy induced-peripheral neuropathy
timeFrame: 8 weeks
measure: the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity(FACT-GOG-NTX) subscale
timeFrame: 8 weeks
measure: Serum nerve growth factor
timeFrame: 8 weeks
measure: Serum malionaldehyde
timeFrame: 8 weeks
Other outcomes:
measure: Adverse effects
timeFrame: 8 weeks
Locations:
city: Mansoura
country: Egypt
facility: Mansoura University
Study officials:
References:
Clinical trial NCT03750396: Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer
Official title: Local Treatment in Addition to Endocrine Therapy in ER-positive/HER2-negative Oligo-metastatic Breast Cancer (CLEAR): a Multicentre, Single -Arm, Phase 2 Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Breast Cancer
Recurrent Breast Cancer
Stereotactic Body Radiotherapy
Estrogen Receptor Positive Tumor
Her2-negative Tumor
Surgery
Keywords: Oligometastasis
Local treatments
Lead sponsor: Gangnam Severance Hospital
Sponsor class: OTHER
Collaborators: name: Severance Hospital
name: Samsung Medical Center
name: Asan Medical Center
First posted: 2018-11-23
Enrollment: 110
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Endocrine therapy is a standard-of-care for 1st line treatment in the patients with ER+/HER2- metastatic breast cancer.

Local treatments for metastatic lesions will be added in this group.

All patients will undergo local treatments in addition to endocrine therapies.

Local treatments include modalities described below:

i) Surgical resection: the achievement of tumor-free margin is not obligatory.

ii) Stereotactic body radiotherapy

iii) Radiofrequency ablation
Primary purpose: TREATMENT

Brief summary: Local treatment in addition to endocrine treatment as 1st line for oligo-metastatic ER-positive/HER2-negative breast cancer.

Detailed description: Local treatment included surgical resection, stereotactic body radiotherapy, palliative radiotherapy, and radiofrequency ablation. Stereotactic body radiotherapy is preferred as a radiation modality.

Endocrine therapies with/without target therapy including CDK4/6 inhibitors or mTOR inhibitors are the mainstay of 1st line treatment for ER-positive/HER2-negative metastatic breast cancer.

Eligibility criteria: Inclusion Criteria:

-ER-positive/HER2-negative in primary tumor

* Oligometastases: ≤ 2 lesions in single organ or site (lung, bone, liver, adrenal glands, distant LNs)
* Recurrent cancer after completion of primary treatment (RFI≥1year)
* Metastatic lesions are feasible for resection or radiotherapy (Size≤3cm)

Exclusion Criteria:

* De Novo metastatic cancer at initial diganosis
* Recurrence-free inverval \< 1 year

Primary outcomes:
measure: Progression-free survival
timeFrame: From the date of registration to the date of first PFS failure or last follow-up; assessed up to 6 years; Median PFS of all registered patients will be over 30 months
Secondary outcomes:
measure: Overall survival
timeFrame: From the date of registration to the date of death or last follow-up; assessed up to 10 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Gangnam Severance Hospital
Study officials:
affiliation: Gangnam Severance Hospital
name: Joon Jeong, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02930096: Study of the Effect of the Supine Position at Brain Velocities in Noncerebro - Injured Patient
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anesthesia General
Lead sponsor: Poitiers University Hospital
Sponsor class: OTHER
First posted: 2016-10-12
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient who need a surgery in supine position and who don't have brain injured or pulmonary desease.

Forty patients over 24 month period were included in the study, after informed consent.

Pulsatility index is mesured with doppler ultrasound:

1. before general anesthesia
2. after general anesthesia in dorsal position
3. in supine position
4. in supine position with 15° proclive Evaluation to the pulsatility index changes in theese position

Brief summary: To evaluate the pulsatility index changes after setting supine position in non brain- injured patient under general anesthesia.


Eligibility criteria: Inclusion Criteria:

* minimum 18 years old, maximum 45 years old for men and 55 years old for women.
* surgery with supine position.

Exclusion Criteria:

* refusal to participate
* failure of measurement brain velocity
* Penthotal or de kétamine before measurment
* Cardiac or pulmonary desease

Primary outcomes:
measure: Evaluation the pulsatility index after setting prone position in non brain-injured patient
timeFrame: 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Poitiers
country: France
facility: DAHYOT FIZELIER Claire
Study officials:
References:
Clinical trial NCT00190996: Evaluate Safety and Efficacy of Duloxetine in Predominant Stress Urinary Incontinence
Official title: The Safety and Effectiveness of Duloxetine Compared With Placebo and Its Long-Term Safety and Efficacy in the Treatment of Predominant Stress Urinary Incontinence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Urinary Incontinence, Stress
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
Collaborators: name: Boehringer Ingelheim
First posted: 2005-09-19
Enrollment: 2765
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purposes of this study are to determine whether duloxetine can help subjects with stress urinary incontinence and to see whether the effects of duloxetine can be maintained.


Eligibility criteria: Inclusion Criteria:

* Female diagnosed with stress urinary incontinence

Exclusion Criteria:

* Currently taking a monoamine oxidase inhibitor

Primary outcomes:
measure: Assess the efficacy of Duloxetine compared with placebo in women with predominant stress urinary incontinence as measured by a reduction in incontinent episode frequency.
Secondary outcomes:
measure: Evaluate the maintenance of effect on IEF in long-term use
measure: Kings Health Questionnaire
measure: Patient Global Impression of Improvement Questionnaire
measure: Safety effects
Other outcomes:
Locations:
city: Surrey
country: United Kingdom
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
citation: Cardozo L, Lange R, Voss S, Beardsworth A, Manning M, Viktrup L, Zhao YD. Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence. Curr Med Res Opin. 2010 Feb;26(2):253-61. doi: 10.1185/03007990903438295.
Clinical trial NCT04594096: Improving Treatment-Related Symptom Management in Adolescents and Young Adults With Cancer
Official title: Improving Treatment-Related Symptom Management in Adolescents and Young Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2020-10-20
Enrollment: 20
Sex: ALL
Minimum age (years): 12
Maximum age (years): 29
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: 2 telehealth visits with a medical provider (either an MD or NP) after last chemotherapy administration in the cycle, or as otherwise indicated
Primary purpose: TREATMENT

Brief summary: This study will test the acceptability and feasibility of a telehealth intervention to improve communication between patients and medical providers in adolescent and young adult (AYA) cancer patients receiving chemotherapy treatment.


Eligibility criteria: Inclusion Criteria:

* Patients with cancer undergoing active treatment and who have received at least two cycles of chemotherapy
* Access to Epic MyChart (we will facilitate access to MyChart for interested patients who are not yet signed up)
* Access to a smartphone or tablet to access EPIC MyChart telehealth appointments

Exclusion Criteria:

* Non-English or non-Spanish speaking patients
* Potentially completing therapy during study period (including follow-up period) or plans to leave UCDCCC during study period

Primary outcomes:
measure: Proportion of Patients Completing the Trial
timeFrame: end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)
Secondary outcomes:
measure: Survey Response Rate
timeFrame: end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)
measure: Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ)
timeFrame: end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: Comprehensive Cancer Center
state: California
Study officials:
References:
Clinical trial NCT01082796: Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects
Official title: Investigate the Relationship Between CYP2C19 Genetic Polymorphisms and Pharmacokinetics of Glipizide in Healthy Chinese Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Genotype
Pharmacokinetic
Lead sponsor: Chinese Academy of Sciences
Sponsor class: OTHER_GOV
Collaborators: name: LanZhou University
First posted: 2010-03-09
Enrollment: 14
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Diabetes mellitus is a growing global disease now and future, and in China, 1.2 million peoples per year have been diagnosed as diabetes mellitus. 90% diabetes mellitus patient is Type 2 diabetes mellitus. Glipizide is a potent drug to service patients who suffer from Type 2 disease. Little information has been presented for the relationship between CYP2C19 genetic polymorphism and glipizide, since recently the investigators reported that there existed a tendency. In this study the investigators found that CYP2C19 polymorphism significantly influenced the pharmacokinetics of glipizide.

Detailed description: Blood samples were obtained from 127 unrelated healthy male Chinese subjects in Gansu Province. After genotyping, 14 subjects (age, 19-26; weight, 59.5-70.0 kg) were enrolled in the study. They were divided into two groups, EMs homo and PMs group. There were no significant differences in age or body weight seen in the two groups.

Each subject received 5 mg glipizide extended release tablet once daily for 7 days. For the first 6 days, glipizide was administered just after a standard breakfast. On day 7, after an overnight fast, each subject received a glipizide extended released tablet (Glucotrol XL, Pfizer, USA) with 100 mL water. Standard meals were given in 4 h and 10 h after dosing. Venous blood samples were collected immediately before and at 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 36, and 48 h after dosing. Blood samples, collected in EDTA tubes, were centrifuged (2500 g) immediately for 10 min and plasma samples separated were stored at -80ºC until assay.

For safety, blood glucose levels were determined directly by use of a Glucose Meter (Accu-Chek, Roche, Germany) at 0, 2, 4, 6, 8, 10, 12, 14, 16, 20and 24 h after last dosing (on day 7).

Eligibility criteria: Inclusion Criteria:

* male
* healthy
* nonsmokers

Exclusion Criteria:

* BMI \> 24 or BMI \< 19
* had any family history of diabetes mellitus

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Lanzhou
country: China
facility: Departmant of Clinical Pharmacology, the First Affiliated Hospital of Lanzhou University
state: Gansu
Study officials:
affiliation: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
name: Da F Zhong, PH.D
role: STUDY_DIRECTOR
References:
Clinical trial NCT01930396: Use of Tinzaparin for Anticoagulation in Hemodialysis
Official title: Intermittent HEMOdialysis Anticoagulation With TINzaparin Versus Unfractionated Heparin: A Pilot Multicentre Randomized Controlled Trial (HEMO-TIN Trial)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Kidney Failure, Chronic
Keywords: Hemodialysis
Anticoagulation
Tinzaparin
Unfractionated Heparin
Randomized Controlled Trial
Lead sponsor: St. Joseph's Healthcare Hamilton
Sponsor class: OTHER
Collaborators: name: McMaster University
name: LEO Pharma
First posted: 2013-08-28
Enrollment: 191
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The HEMO-TIN trial is designed to look at both the safety (bleeding risk) and effectiveness (clotting risk) of tinzaparin compared with unfractionated heparin for anticoagulation in hemodialysis patients.


Eligibility criteria: Inclusion Criteria:

* Age \>= 18 years
* End stage renal disease maintained on outpatient hemodialysis for \>= 3 months
* Frequency of hemodialysis: 3 times per week
* Anticoagulation with an unfractionated heparin protocol for at least 4 weeks
* Patient or legal guardian able to provide written consent
* Baseline INR \<= 1.3
* Baseline platelet count \>= 80,000 x 10\^9/L

Exclusion Criteria:

* Therapeutic systemic anticoagulation
* Clinically apparent bleeding in the last 2 months
* High risk of bleeding
* Planned major surgery in the next 4 months
* Major surgery in the past 48 hours
* Pregnant or lactating
* Child bearing potential
* Allergy/intolerance to heparin or history of heparin induced thrombocytopenia
* Current participation in a related randomized drug trial

Primary outcomes:
measure: Rate of major, clinically important non-major or minor bleeding
timeFrame: 26 weeks
Secondary outcomes:
measure: Clotting in extracorporeal dialysis circuit
timeFrame: During Hemodialysis (weekly for 26 weeks)
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: St. Joseph's Healthcare Hamilton
state: Ontario
Study officials:
affiliation: St. Joseph's Healthcare Hamilton/McMaster University
name: Dr. Christine M Ribic, MD, MSc
role: PRINCIPAL_INVESTIGATOR
References: